#1 Clinical Trials Search in Europe

Norucholic Acid

Norucholic Acid, also known as norursodeoxycholic acid (norUDCA), is currently being studied in clinical trials for its potential to treat various liver conditions. This article explores two significant trials investigating the drug’s effectiveness in treating Non-alcoholic Steatohepatitis (NASH) and Primary Sclerosing Cholangitis (PSC). These studies aim to determine if Norucholic Acid can improve liver health and slow disease progression in patients with these challenging conditions.

Table of Contents

What is Norucholic Acid?

Norucholic acid, also known as norursodeoxycholic acid (norUDCA), norUrsodeoxycholic acid, or NCA, is a promising new medication being studied for the treatment of certain liver diseases[1][2]. It is a modified form of ursodeoxycholic acid, a naturally occurring bile acid that has been used to treat various liver conditions.

Conditions Treated

Norucholic acid is currently being investigated for the treatment of two main liver conditions:

  • Non-alcoholic Steatohepatitis (NASH): This is a severe form of non-alcoholic fatty liver disease characterized by inflammation and damage to liver cells. It can lead to scarring of the liver (fibrosis) and potentially progress to cirrhosis[1].
  • Primary Sclerosing Cholangitis (PSC): This is a chronic liver disease that causes inflammation and scarring of the bile ducts, both inside and outside the liver. Over time, this can lead to liver damage and failure[2].

How It Works

While the exact mechanism of action is still being studied, norucholic acid is believed to work by:

  • Reducing inflammation in the liver
  • Improving the flow of bile (a digestive fluid produced by the liver)
  • Potentially slowing down or reversing liver damage and scarring

These effects may help in managing both NASH and PSC by addressing the underlying causes of liver damage[1][2].

Dosage and Administration

Norucholic acid is being tested in different dosages and forms:

  • For NASH: It is being studied as film-coated tablets in doses of 1000 mg/day or 1500 mg/day, taken as three tablets once daily[1].
  • For PSC: It is being tested as capsules, with a dosage of 1500 mg/day, taken as six 250 mg capsules daily[2].

It’s important to note that these dosages are specific to the clinical trials and may change based on the results and further research.

Clinical Trials

Norucholic acid is currently undergoing rigorous clinical trials to evaluate its safety and effectiveness:

  • For NASH: A Phase IIb trial is being conducted to compare two different doses of norucholic acid (1000 mg/day and 1500 mg/day) against a placebo. This study aims to assess the drug’s ability to resolve NASH and improve liver fibrosis over a 72-week treatment period[1].
  • For PSC: A Phase III trial is underway, comparing 1500 mg/day of norucholic acid against a placebo over a 2-year period. This study aims to evaluate the drug’s effectiveness in slowing disease progression and improving liver function in PSC patients[2].

Both trials are double-blind, randomized, and placebo-controlled, which means neither the patients nor the researchers know who is receiving the actual drug or the placebo during the study. This design helps ensure unbiased results.

Potential Benefits

If successful, norucholic acid could offer several benefits for patients with NASH or PSC:

  • For NASH patients: The drug may help resolve inflammation and prevent worsening of liver fibrosis. This could potentially halt or slow the progression of the disease[1].
  • For PSC patients: Norucholic acid may help normalize liver enzyme levels, particularly alkaline phosphatase (ALP), which is an indicator of liver and bile duct health. It may also improve liver histology, potentially slowing down the progression of the disease[2].

It’s important to remember that while these potential benefits are promising, the drug is still in the testing phase. More research is needed to fully understand its effectiveness and safety profile.

Aspect NASH Trial (NCT05083390) PSC Trial (NCT03872921)
Condition Studied Non-alcoholic Steatohepatitis (NASH) Primary Sclerosing Cholangitis (PSC)
Study Phase Phase IIb Phase III
Treatment Groups 3 (1500 mg/day, 1000 mg/day, Placebo) 2 (1500 mg/day, Placebo)
Administration Form Film-coated tablets Capsules
Duration 72 weeks 2 years
Primary Outcomes Resolution of NASH, no worsening of fibrosis, improvement of fibrosis, no worsening of NAS Partial normalization of s-ALP levels, prevention of disease progression assessed by liver histology

FAQ

  • What is Norucholic Acid? Norucholic Acid, also called norursodeoxycholic acid (norUDCA), is a drug being studied for its potential to treat liver diseases. It's a modified form of a naturally occurring bile acid and is being tested in clinical trials for conditions like Non-alcoholic Steatohepatitis (NASH) and Primary Sclerosing Cholangitis (PSC).
  • What conditions are being studied with Norucholic Acid? The clinical trials are focusing on two main liver conditions: Non-alcoholic Steatohepatitis (NASH) and Primary Sclerosing Cholangitis (PSC). NASH is a type of fatty liver disease, while PSC is a chronic liver disease that causes inflammation and scarring of the bile ducts.
  • How is Norucholic Acid administered in these trials? In the NASH trial, Norucholic Acid is given as film-coated tablets, with patients taking 3 tablets once daily. The dosages being tested are 1500 mg/day and 1000 mg/day. In the PSC trial, it's administered as capsules, with patients taking 6 capsules per day for a total of 1500 mg/day.
  • How long do the clinical trials last? The duration of the trials varies. The NASH trial lasts for 72 weeks (about 1.5 years), while the PSC trial continues for 2 years. These extended periods allow researchers to assess the long-term effects and safety of the drug.
  • What are the main outcomes being measured in these trials? For the NASH trial, researchers are looking at the resolution of NASH and improvement in liver fibrosis. In the PSC trial, the main outcomes include the normalization of serum Alkaline Phosphatase (s-ALP) levels and improvements in liver histology, both indicators of reduced disease progression.

Ongoing Clinical Trials on Norucholic Acid

  • Study on the Safety and Tolerability of Norucholic Acid Tablets for Patients with Primary Sclerosing Cholangitis (PSC)

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Belgium Denmark France Germany Hungary +4

  • Study on Norucholic Acid for Treating Primary Sclerosing Cholangitis in Patients

    Not recruiting

    3 1
    Investigated drugs:
    Austria Denmark Finland France Germany Hungary +3

Glossary

  • Norucholic Acid: Also known as norursodeoxycholic acid (norUDCA), it's a modified form of a naturally occurring bile acid being studied for its potential to treat liver diseases.
  • Non-alcoholic Steatohepatitis (NASH): A type of fatty liver disease characterized by inflammation and damage to liver cells, which can lead to scarring and reduced liver function.
  • Primary Sclerosing Cholangitis (PSC): A chronic liver disease that causes inflammation and scarring of the bile ducts, both inside and outside the liver, potentially leading to liver damage and failure.
  • Placebo: An inactive substance that looks like the real medicine but has no therapeutic effect, used as a control in clinical trials to test the effectiveness of drugs.
  • Double-blind: A study design where neither the participants nor the researchers directly involved know who is receiving the actual treatment and who is receiving a placebo.
  • Randomized: A method of assigning participants to different treatment groups by chance, which helps reduce bias in clinical trials.
  • Fibrosis: The formation of excess fibrous connective tissue in an organ, often as a result of injury or chronic inflammation.
  • Histology: The study of the microscopic structure of tissues, often used to assess the progression or improvement of liver diseases.
  • Serum Alkaline Phosphatase (s-ALP): An enzyme found in various tissues, particularly liver and bone. Elevated levels in the blood can indicate liver disease or bone disorders.
  • NAS (NAFLD Activity Score): A scoring system used to assess the severity of Non-alcoholic Fatty Liver Disease (NAFLD) and NASH based on liver biopsy findings.

References

  1. https://clinicaltrials.gov/study/NCT05083390
  2. https://clinicaltrials.gov/study/NCT03872921